In its third ac­qui­si­tion of 2026, Gilead is splash­ing $3.15 bil­lion up­front to snag a next-gen­er­a­tion an­ti­body-drug con­ju­gate plat­form from Ger­man start­up Tubu­lis. The Cal­i­for­nia bio­phar­ma could dish out an­oth­er $1.85 bil­lion down the road to Tubu­lis share­hold­ers if all goes well with the ac­qui­si­tion, which was an­nounced Tues­day morn­ing...